Leukapheresis Market

7500+ companies worldwide approach us every year for their revenue growth initiatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT

Report Code: MD 6538 Aug, 2023, by marketsandmarkets.com

The global leukapheresis market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 million by 2028, growing at a CAGR of 8.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The global leukopaks market was estimated to be worth USD 200 million in 2023 and is poised to reach USD 1020 million by 2028, growing at a CAGR of 38.1%.

One of the key trends in the leukapheresis market is the increasing use of leukopaks in CAR T-cell therapy. CAR T-cell therapy is a type of immunotherapy that uses the patient's own immune cells to fight cancer. It is a promising new treatment for leukemia and other blood cancers. Leukopaks are used to collect the patient's immune cells, which are then modified to fight cancer. Other trends in the leukapheresis market include the increasing demand for leukopaks in personalized medicine and the development of new leukopak collection and storage methods.

Attractive Opportunities in the Leukapheresis Products Market

Leukapheresis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Leukapheresis Market

Leukapheresis Market Dynamics

Driver: Increased demand for leukopaks in clinical research

Leukopaks are enriched leukapheresis products collected from peripheral blood and consist of various blood cells, including lymphocytes, monocytes, and dendritic cells. Leukopaks are a good source of a variety of immune cells. The need for human cells in any kind of research in the fields of oncology, immunotherapy, or cell biology is the key factor supporting the demand for leukopaks.

On the other hand, pharmaceutical and biotechnology companies have shown a greater focus on developing cell-based immunotherapies, such as CAR-T therapy for leukemia. CAR-T therapy involves using T-cells isolated from leukopaks for the development of genetically altered chimeric antigen receptor T-cells. Approximately 300 pharmaceutical companies are engaged in CAR-T therapy R&D. According to ClinicalTrials.gov, as of August 2023, 316 CAR T-cell-related studies are underway in the US. As of April 2023, six CAR T cell therapies have been approved, indicating unprecedented efficacy in patients with B-cell malignancies and multiple myeloma. Nonetheless, adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity pose substantial challenges to CAR T cell therapy.

Restraint: Complications associated with therapeutic leukapheresis

Therapeutic leukapheresis is associated with certain complications, such as those arising from a decreased WBC count and the possibility of adverse interactions with anticoagulation solutions. Moreover, there may be discomfort, pain, redness, and bruising at the venipuncture site. The procedure may also cause patients to feel dizzy for a short duration and cause loss of consciousness.

Hypocalcemia, decreased calcium levels also occurs in a large volume of leukapheresis procedures. Slowing the procedure, decreasing the amount of anticoagulation, and administering oral or intravenous calcium supplementation are recommended in such conditions.

Furthermore, minor degrees of RBC or platelet loss have been reported. Apheresis systems separate WBCs and return the remaining blood to the patient according to different manufacturer settings that may influence hemoglobin or hematocrit levels. This could create major risks for donors with a history of anemia and thrombocytopenia.

WBC transfusion for the treatment of neutropenia and granulocyte deficiencies increases the risk of causing an immune response against transfused WBCs. Major complications associated with therapeutic leukapheresis procedures include pulmonary leukostasis, acute renal failure, and sometimes even death.

Opportunity: Gaps in current leukapheresis technologies

The gaps in current technologies are primarily linked to incomplete or non-cost-effective removal or separation efficiency of bio-products, potential side effects to patients and damage induced to cells during the extraction processes. According to a 2021 study published in the Royal Society of Chemistry, further research needs to take place on interfacial chemistries between the blood and the membrane materials it interacts with.

Additionally, biocompatible materials such as amphiphilic/zwitterionic polymers can also be explored as coating materials for use in leukapheresis membranes for enhanced hemocompatibility. These present opportunities areas to fill the gaps in leukapheresis technologies for the various manufacturers of various leukapheresis products and researchers in the market.

Challenge: Blood transfusion safety in developing countries

Blood transfusion is a life-saving medical procedure that involves the transfer of blood or blood products from a healthy donor to a recipient. It is used to treat a variety of medical conditions, including anemia, hemorrhage, and cancer. The risk of transfusion-transmitted infections (TTIs) is high in developing countries. TTIs are infections that can be transmitted through blood transfusion. Some of the most common TTIs include HIV, hepatitis B, and hepatitis C. The leukepheresis market is also a major concern in developing countries. This is due to the high cost of leukapheresis equipment and procedures. In addition, there is often a shortage of qualified personnel to perform leukapheresis.

Despite these challenges, there are a number of developments that are being made to improve blood transfusion safety in developing countries. These developments include the development of new blood safety technologies, the training of healthcare workers and the development of blood safety policies and regulations. The improvement of blood transfusion safety in developing countries is a complex challenge. However, the developments that are being made are helping to make blood transfusion safer for patients in these countries.

According to the World Health Organization (WHO), TTIs are responsible for an estimated 1.5 million deaths each year. The risk of TTIs is highest in developing countries, where the infrastructure and resources for blood safety are often lacking. In sub-Saharan Africa, for example, the risk of HIV transmission through blood transfusion is estimated to be 1 in 250. The WHO has set a goal of making blood transfusion safe in all countries by 2020. However, this goal is unlikely to be met, as many developing countries are still struggling to improve blood transfusion safety.

Despite the challenges, there are a number of reasons to be hopeful about the future of blood transfusion safety in developing countries. The developments that are being made, such as the development of new blood safety technologies and the training of healthcare workers, are helping to make blood transfusion safer for patients in these countries. With continued efforts, it is possible to make blood transfusion safe for everyone, regardless of where they live.

Leukapheresis Market Ecosystem

Leading players in this market include well-established and financially stable manufacturers of leukapheresis. These companies have been operating in the market for several years and possess a diversified product portfolio, advanced technologies, and strong global presence. Prominent companies in this market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).

Leukapheresis Market Ecosystem

The leukapheresis devices segment is expected to register the highest CAGR during the forecast period.

The leukapheresis devices segment is projected to grow at the highest CAGR during 2023 to 2028. The growth of the leukapheresis devices market can largely be attributed to the increasing number of therapeutic leukapheresis procedures conducted for the treatment of leukemia, immune-mediated inflammatory diseases, and inflammatory bowel diseases. The increasing adoption of leukapheresis instruments by blood collection centers is another major factor supporting market growth.

The centrifugal devices segment of leukapheresis industry is expected to register the highest CAGR during the forecast period.

The centrifugal devices segment of the leukapheresis market is projected to grow at a higher CAGR during the forecast period 2023 to 2028. Centrifugal apheresis devices are widely used for leukapheresis, blood collection, automated blood component separation, therapeutic plasma exchange, and erythrocytapheresis. Some of the players offering centrifugal devices are Haemonetics Corporation (US), Nikkiso Co., Ltd. (Japan), MacoPahrma SA (France), Terumo BCT (US) and Fresenius Kabi (Germany).

APAC is estimated to be the fastest-growing regional market for leukapheresis industry.

In 2022, North America accounted for the largest share of the leukapheresis market. Factors like the developed healthcare system in the US and Canada, the presence of a large number of leukopak manufacturing companies in the region, and the easy accessibility to technologically advanced blood separation devices contribute to the growth of this region. Additionally, in 2022, APAC is estimated to be the fastest-growing regional market for leukapheresis. This growth is driven by factors such as the presence of a large number of pharma & biotech companies and research institutes in China and India and the improving life science research infrastructure in several Asia Pacific countries contribute to the growth of this region.

Leukapheresis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the leukapheresis market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).

Some prominent players in the leukapheresis market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US). These companies adopted strategies such as service launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.

Scope of the Leukapheresis Industry:

Report Metric	Details
Market Revenue in 2023	$70 million
Estimated Value by 2028	$100 million
Revenue Rate	Poised to grow at a CAGR of 8.3%
Market Driver	Increased demand for leukopaks in clinical research
Market Opportunity	Gaps in current leukapheresis technologies

The study categorizes the leukapheresis market to forecast revenue and analyze trends in each of the following submarkets:

By Leukapheresis Products

By Product Type

Leukapheresis Devices
- Centrifugal Devices
- Membrane Separators
Leukapheresis Disposables

By Application

Research Applications
Therapeutic Applications

By End User

Hospitals & Transfusion Centers
Component Providers & Blood Centers
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies

By Leukopaks

By Type

Mobilized Leukopaks
Non-Mobilized Leukopaks
Diseased Leukopaks
Isolated PBMCs

By Indications

Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin’s Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Pancreatic Cancer
Other Indications

By End User

Contract Research Organizations (CROs)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies

By Region

North America
- US
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
Middle East & Africa

Recent Developments of Leukapheresis Industry

In May 2022, Fresenius Kabi (Germany) acquired Ivenix, Inc. (US). This acquisition adds a next-generation infusion therapy platform for the significant US market to Fresenius Kabi’s portfolio and provides the company with key capabilities in hospital connectivity.
In March 2022, Charles River Laboratories International Inc. (US) acquired Retrogenix Limited (UK) to enhance the company’s scientific expertise with additional large molecule and cell therapy discovery capabilities.
In November 2021, Discovery Life Sciences (US) announced the launch of the Discovery BIOstore, which provides real-time access to Discovery’s inventory of millions of human biospecimens to scientists.

Frequently Asked Questions (FAQ):

What is the projected market revenue value of the global leukapheresis market?

The global leukapheresis market boasts a total revenue value of $100 million by 2028.

What is the estimated growth rate (CAGR) of the global leukapheresis market?

The global leukapheresis market has an estimated compound annual growth rate (CAGR) of 8.3% and a revenue size in the region of $70 million in 2023.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 37)

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 TYPE

1.2.2 APPLICATION

1.2.3 END USER

1.2.4 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED

1.4 CURRENCY CONSIDERED

TABLE 1 STANDARD CURRENCY CONVERSION RATES

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 43)

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 2 PRIMARY SOURCES

2.1.2.1 Key data from primary sources

2.1.2.2 Insights from primary experts

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS MARKET)

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)

FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS MARKET SIZE)

FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)

FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS MARKET)

2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS PRODUCTS MARKET

FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2022)

FIGURE 10 REVENUE ANALYSIS OF TOP FOUR COMPANIES: LEUKAPHERESIS MARKET (2022)

FIGURE 11 DEMAND-SIDE APPROACH: LEUKAPHERESIS PRODUCTS MARKET (2022)

FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028)

FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS MARKET SIZE)

FIGURE 14 TOP-DOWN APPROACH

2.3 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET

FIGURE 15 VOLUME ESTIMATION OF LEUKAPHERESIS MARKET

FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS MARKET SIZE)

FIGURE 17 TOP-DOWN APPROACH

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 18 MARKET DATA TRIANGULATION METHODOLOGY

2.5 MARKET SHARE ANALYSIS

2.6 RESEARCH ASSUMPTIONS

2.7 RISK ASSESSMENT

TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKAPHERESIS MARKETS

2.8 METHODOLOGY-RELATED LIMITATIONS

2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 64)

FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 20 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 21 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 22 LEUKAPHERESIS MARKET SIZE, BY END USER, 2023 VS. 2028 (USD MILLION)

FIGURE 23 LEUKOPAKS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 24 LEUKAPHERESIS MARKET FORECAST, BY INDICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 25 LEUKAPHERESIS MARKET FORECAST, BY END USER, 2023 VS. 2028 (USD MILLION)

FIGURE 26 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET

FIGURE 27 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS MARKET FORECAST

4 PREMIUM INSIGHTS (Page No. - 71)

4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW

FIGURE 28 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET

4.2 NORTH AMERICA: LEUKAPHERESIS MARKET FORECAST, BY TYPE AND COUNTRY

FIGURE 29 DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2022

4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX

FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

4.4 LEUKAPHERESIS MARKET FORECAST: REGIONAL MIX

FIGURE 31 NORTH AMERICA DOMINATED MARKET IN 2022

4.5 LEUKOPAKS MARKET: OVERVIEW

FIGURE 32 RISING DEMAND FOR LEUKOPAKS FOR USE IN RESEARCH APPLICATIONS TO DRIVE MARKET

4.6 NORTH AMERICA: LEUKAPHERESIS MARKET TRENDS, BY PRODUCT AND COUNTRY

FIGURE 33 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2022

4.7 LEUKAPHERESIS MARKET TRENDS: GEOGRAPHIC MIX

FIGURE 34 CHINA TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD

4.8 LEUKAPHERESIS MARKET TRENDS: REGIONAL MIX

FIGURE 35 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 76)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 36 LEUKAPHERESIS MARKET TRENDS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Rising incidence and prevalence of leukemia

FIGURE 37 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020–2040)

FIGURE 38 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020–2040)

5.2.1.2 Increasing blood donation

5.2.1.3 Growing demand for leukopaks in clinical research

FIGURE 39 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009–2020

FIGURE 40 NUMBER OF CAR-T THERAPY CLINICAL TRIALS: US VS. CHINA, 2022

5.2.2 RESTRAINTS

5.2.2.1 High cost of therapeutic leukapheresis and leukopaks

TABLE 3 COST OF LEUKOPAKS, BY TYPE

5.2.2.2 Stringent donor recruitment criteria

TABLE 4 DONOR SELECTION CRITERIA

TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS

5.2.2.3 Dearth of skilled professionals

5.2.2.4 Complications associated with therapeutic leukapheresis

5.2.2.5 Long duration of procedure

5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement

5.2.3 OPPORTUNITIES

5.2.3.1 Growing focus on leukapheresis for pediatric patients

5.2.3.2 Increasing investments in CAR-T therapies in emerging economies

5.2.3.3 Gaps in current leukapheresis technologies

5.2.4 CHALLENGES

5.2.4.1 Concerns related to safety of blood transfusion in emerging economies

5.3 PORTER’S FIVE FORCES ANALYSIS

FIGURE 41 PORTER’S FIVE FORCES ANALYSIS: LEUKAPHERESIS MARKET

TABLE 6 LEUKAPHERESIS MARKET TRENDS: PORTER’S FIVE FORCES ANALYSIS

5.3.1 THREAT FROM NEW ENTRANTS

5.3.2 THREAT FROM SUBSTITUTES

5.3.3 BARGAINING POWER OF SUPPLIERS

5.3.4 BARGAINING POWER OF BUYERS

5.3.5 INTENSITY OF COMPETITIVE RIVALRY

5.4 INDUSTRY TRENDS

5.4.1 INCREASING COLLABORATIONS BETWEEN PHARMA AND BIOTECH COMPANIES

TABLE 7 RECENT DEVELOPMENTS RELATED TO CAR-T THERAPY

5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS

5.5 TECHNOLOGY ANALYSIS

5.5.1 KEY TECHNOLOGIES

5.5.1.1 Centrifugal-based leukapheresis

5.5.1.2 Membrane-based leukapheresis

TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION

5.5.2 EMERGING TECHNOLOGIES

5.5.2.1 Adsorption-based leukapheresis

5.5.2.2 Microfluidic devices for leukapheresis

5.5.2.3 Integration of AI in leukapheresis treatment

5.6 PRICING ANALYSIS (LEUKOPAKS MARKET)

TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS

TABLE 10 ASP OF MOBILIZED LEUKOPAKS

TABLE 11 ASP OF MOBILIZED ISOLATED CELLS

5.7 KEY CONFERENCES AND EVENTS, 2023–2024

TABLE 12 LEUKAPHERESIS MARKET OVERVIEW: CONFERENCES AND EVENTS

5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)

5.8.1 NORTH AMERICA

5.8.1.1 US

5.8.1.2 Canada

5.8.2 EUROPE

5.8.3 ASIA PACIFIC

5.8.3.1 Japan

5.8.3.2 China

5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.10 REGULATORY ANALYSIS (LEUKAPHERESIS MARKET OVERVIEW)

5.10.1 US

TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS

5.10.2 EUROPE

5.10.3 JAPAN

5.10.4 INDIA

5.11 VALUE CHAIN ANALYSIS

FIGURE 42 VALUE CHAIN: LEUKAPHERESIS MARKET OVERVIEW (LEUKAPHERESIS SYSTEMS)

5.12 SUPPLY CHAIN ANALYSIS

FIGURE 43 LEUKAPHERESIS MARKET OVERVIEW: STAKEHOLDERS IN SUPPLY CHAIN

5.13 ECOSYSTEM ANALYSIS

FIGURE 44 LEUKAPHERESIS MARKET OVERVIEW: ECOSYSTEM MAP

TABLE 19 LEUKAPHERESIS MARKET GROWTH: ECOSYSTEM

5.14 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS

5.15 PATENT ANALYSIS

5.15.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET

FIGURE 45 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS MARKET, JANUARY 2019–AUGUST 2023

5.15.2 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS MARKET GROWTH

FIGURE 46 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS MARKET, JANUARY 2019–AUGUST 2023

5.15.3 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS

FIGURE 47 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023

5.15.4 TOP APPLICANTS FOR LEUKOPAK PATENTS

FIGURE 48 TOP APPLICANTS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023

5.15.5 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS MARKET PATENTS

FIGURE 49 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2019–AUGUST 2023

FIGURE 50 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023

5.15.6 TOP PATENT APPLICANTS/OWNERS

FIGURE 51 TOP APPLICANTS AND OWNERS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023

FIGURE 52 TOP APPLICANTS AND OWNERS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023

TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: MAJOR PATENTS (2020–2022)

TABLE 21 LEUKAPHERESIS MARKET GROWTH: MAJOR PATENTS (2019–2022)

5.16 KEY STAKEHOLDERS AND BUYING CRITERIA

5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 53 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS

TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS

5.16.2 BUYING CRITERIA

FIGURE 54 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS

TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS

5.17 CASE STUDIES

TABLE 24 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL

TABLE 25 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL

5.18 ADJACENT MARKET ANALYSIS

5.18.1 PLASMA FRACTIONATION MARKET

FIGURE 55 PLASMA FRACTIONATION MARKET OVERVIEW

5.18.2 APHERESIS MARKET

FIGURE 56 APHERESIS MARKET OVERVIEW

6 LEUKAPHERESIS MARKET GROWTH, BY TYPE (Page No. - 121)

6.1 INTRODUCTION

TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 27 LEUKAPHERESIS MARKET GROWTH, BY COUNTRY, 2021–2028 (USD MILLION)

6.2 DISPOSABLES

6.2.1 RECURRENT DEMAND TO BOOST SEGMENT

TABLE 28 LEUKOREDUCTION FILTER MANUFACTURERS

TABLE 29 LEUKAPHERESIS COLUMN AND CELL SEPARATOR MANUFACTURERS

TABLE 30 DISPOSABLES: LEUKAPHERESIS MARKET REPORT, BY COUNTRY, 2021–2028 (USD MILLION)

6.3 DEVICES

TABLE 31 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 32 DEVICES: LEUKAPHERESIS MARKET REPORT, BY COUNTRY, 2021–2028 (USD MILLION)

6.3.1 CENTRIFUGAL DEVICES

6.3.1.1 Increasing installation in hospitals to drive market

TABLE 33 CENTRIFUGAL DEVICES AVAILABLE

TABLE 34 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

6.3.2 MEMBRANE SEPARATORS

6.3.2.1 Difficulty in separating large volumes of plasma to limit market

TABLE 35 MEMBRANE SEPARATORS AVAILABLE

TABLE 36 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

7 LEUKAPHERESIS MARKET REPORT, BY APPLICATION (Page No. - 131)

7.1 INTRODUCTION

TABLE 37 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

7.2 RESEARCH APPLICATIONS

7.2.1 GROWING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT

TABLE 38 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES

TABLE 39 RESEARCH APPLICATIONS: LEUKAPHERESIS MARKET REPORT, BY COUNTRY, 2021–2028 (USD MILLION)

7.3 THERAPEUTIC APPLICATIONS

7.3.1 RISING ADOPTION OF LEUKAPHERESIS FOR LEUKEMIA TREATMENT TO FUEL MARKET

TABLE 40 THERAPEUTIC APPLICATIONS: LEUKAPHERESIS MARKET REPORT, BY COUNTRY, 2021–2028 (USD MILLION)

8 LEUKAPHERESIS MARKET DEMAND, BY END USER (Page No. - 135)

8.1 INTRODUCTION

TABLE 41 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS

8.2.1 INCREASING BLOOD DONATION TO DRIVE MARKET

TABLE 42 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS: LEUKAPHERESIS MARKET DEMAND, BY COUNTRY, 2021–2028 (USD MILLION)

8.3 ACADEMIC & RESEARCH INSTITUTES

8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET

TABLE 43 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS MARKET DEMAND, BY COUNTRY, 2021–2028 (USD MILLION)

8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT

TABLE 44 PHARMA-BIOTECH COMPANIES DEVELOPING CAR-T CELL TECHNOLOGIES

TABLE 45 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS MARKET DEMAND, BY COUNTRY, 2021–2028 (USD MILLION)

8.5 HOSPITALS & TRANSFUSION CENTERS

8.5.1 GROWING NEED FOR TRANSFUSIONS TO PROPEL MARKET

TABLE 46 HOSPITALS & TRANSFUSION CENTERS: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

9 LEUKAPHERESIS MARKET DEMAND, BY TYPE (Page No. - 143)

9.1 INTRODUCTION

TABLE 47 LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 48 LEUKAPHERESIS MARKET ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)

9.2 MOBILIZED LEUKOPAKS

9.2.1 INCREASING USE IN CLINICAL RESEARCH TO DRIVE MARKET

TABLE 49 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS

TABLE 50 MOBILIZED LEUKAPHERESIS MARKET SEGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 51 MOBILIZED LEUKAPHERESIS MARKET ANALYSIS, BY REGION, 2021–2028 (UNITS)

9.3 NON-MOBILIZED LEUKOPAKS

9.3.1 LOW COST TO PROPEL MARKET

TABLE 52 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS

TABLE 53 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS

TABLE 54 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS

TABLE 55 NON-MOBILIZED LEUKAPHERESIS MARKET SEGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 56 NON-MOBILIZED LEUKAPHERESIS MARKET ANALYSIS, BY REGION, 2021–2028 (UNITS)

9.4 DISEASED LEUKOPAKS

9.4.1 RISING USE FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO BOOST MARKET

TABLE 57 DISEASED LEUKAPHERESIS MARKET SEGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 58 DISEASED LEUKAPHERESIS MARKET ANALYSIS, BY REGION, 2021–2028 (UNITS)

9.5 ISOLATED PBMCS

9.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET

TABLE 59 IMMUNE CELL TYPES AND TARGETED DISEASES

TABLE 60 ISOLATED PBMCS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 61 ISOLATED PBMCS MARKET, BY REGION, 2021–2028 (UNITS)

10 LEUKAPHERESIS MARKET ANALYSIS, BY INDICATION (Page No. - 154)

10.1 INTRODUCTION

FIGURE 57 NUMBER OF GLOBAL CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CELLS

TABLE 62 LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

10.2 ACUTE LYMPHOCYTIC LEUKEMIA

10.2.1 RISING INCIDENCE OF DISEASE TO DRIVE MARKET

TABLE 63 ACUTE LYMPHOCYTIC LEUKEMIA: LEUKAPHERESIS MARKET SEGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

10.3 MULTIPLE MYELOMA

10.3.1 RISING DIAGNOSIS RATE TO FUEL SEGMENT

FIGURE 58 INCIDENCE OF MULTIPLE MYELOMA IN 2020

TABLE 64 MULTIPLE MYELOMA: LEUKAPHERESIS MARKET SEGMENTATION, BY COUNTRY, 2021–2028 (USD MILLION)

10.4 NON-HODGKIN’S LYMPHOMA

10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET

TABLE 65 NON-HODGKIN’S LYMPHOMA: LEUKAPHERESIS MARKET SEGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)

10.5 CHRONIC LYMPHOCYTIC LEUKEMIA

10.5.1 RISING NUMBER OF CASES TO PROPEL MARKET

TABLE 66 CHRONIC LYMPHOCYTIC LEUKEMIA: LEUKAPHERESIS MARKET SEGMENTATION, BY COUNTRY, 2021–2028 (USD MILLION)

10.6 PANCREATIC CANCER

10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT

FIGURE 59 INCIDENCE OF PANCREATIC CANCER IN 2020

TABLE 67 PANCREATIC CANCER: LEUKAPHERESIS MARKET SEGMENTATION, BY COUNTRY, 2021–2028 (USD MILLION)

10.7 HEPATOCELLULAR CARCINOMA

10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT

TABLE 68 HEPATOCELLULAR CARCINOMA: LEUKAPHERESIS MARKET SEGMENTATION, BY COUNTRY, 2021–2028 (USD MILLION)

10.8 OTHER INDICATIONS

TABLE 69 OTHER INDICATIONS: LEUKAPHERESIS MARKET SEGMENTATION, BY COUNTRY, 2021–2028 (USD MILLION)

11 LEUKAPHERESIS MARKET PREDICTION, BY END USER (Page No. - 167)

11.1 INTRODUCTION

TABLE 70 LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2 ACADEMIC & RESEARCH INSTITUTES

11.2.1 INCREASING INDUSTRY−ACADEMIC RESEARCH PARTNERSHIPS TO DRIVE MARKET

TABLE 71 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS MARKET PREDICTION, BY COUNTRY, 2021–2028 (USD MILLION)

11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT TO PROPEL MARKET

FIGURE 60 PERCENTAGE OF GLOBAL CAR-T DRUGS IN US AND CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT

TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS MARKET PREDICTION, BY COUNTRY, 2021–2028 (USD MILLION)

11.4 CONTRACT RESEARCH ORGANIZATIONS

11.4.1 INCREASING CLINICAL TRIAL SPONSORSHIP TO DRIVE MARKET

TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: LEUKAPHERESIS MARKET PREDICTION, BY COUNTRY, 2021–2028 (USD MILLION)

12 LEUKAPHERESIS MARKET PREDICTION, BY REGION (Page No. - 172)

12.1 INTRODUCTION

FIGURE 61 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

TABLE 74 LEUKAPHERESIS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)

FIGURE 62 LEUKAPHERESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

TABLE 75 LEUKOPAKS MARKET, BY REGION, 2021–2028 (USD MILLION)

12.2 NORTH AMERICA

12.2.1 RECESSION IMPACT: NORTH AMERICA

FIGURE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT

TABLE 76 NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 78 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 79 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 80 NORTH AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 81 NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 82 NORTH AMERICA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 83 NORTH AMERICA: LEUKAPHERESIS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 84 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)

12.2.2 US

12.2.2.1 Presence of leading pharmaceutical and biotechnology companies to drive market

TABLE 85 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG)

TABLE 86 US: KEY MACROINDICATORS

TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 88 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 89 US: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 90 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 91 US: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 92 US: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 93 US: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.2.3 CANADA

12.2.3.1 Rising prevalence of blood cancer to stimulate market growth

TABLE 94 CANADA: KEY MACROINDICATORS

TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 96 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 97 CANADA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 98 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 99 CANADA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 100 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 101 CANADA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.3 EUROPE

12.3.1 RECESSION IMPACT: EUROPE

FIGURE 64 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT

TABLE 102 EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 104 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 105 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 106 EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 107 EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 108 EUROPE: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 109 EUROPE: LEUKAPHERESIS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 110 EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)

12.3.2 UK

12.3.2.1 Rising awareness of cell-based therapies to propel market

TABLE 111 UK: KEY MACROINDICATORS

TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 113 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 114 UK: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 115 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 116 UK: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 117 UK: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 118 UK: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.3.3 GERMANY

12.3.3.1 Increasing research on cancer immunotherapies to boost market

TABLE 119 GERMANY: KEY MACROINDICATORS

TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 121 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 122 GERMANY: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 123 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 124 GERMANY: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 125 GERMANY: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 126 GERMANY: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.3.4 SPAIN

12.3.4.1 Rising focus on development of novel CAR-T cell therapies to fuel market

TABLE 127 SPAIN: KEY MACROINDICATORS

TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 129 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 130 SPAIN: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 131 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 132 SPAIN: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 133 SPAIN: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 134 SPAIN: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.3.5 FRANCE

12.3.5.1 Government healthcare initiatives to drive market

TABLE 135 FRANCE: KEY MACROINDICATORS

TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 137 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 138 FRANCE: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 139 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 140 FRANCE: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 141 FRANCE: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 142 FRANCE: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.3.6 ITALY

12.3.6.1 Increasing adoption of cell-based therapies to boost market

TABLE 143 ITALY: COMMERCIAL CAR-T CELL THERAPIES APPROVED BY EMA (2022)

TABLE 144 ITALY: KEY MACROINDICATORS

TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 146 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 147 ITALY: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 148 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 149 ITALY: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 150 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 151 ITALY: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.3.7 REST OF EUROPE

TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 153 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 154 REST OF EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 155 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 156 REST OF EUROPE: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 157 REST OF EUROPE: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 158 REST OF EUROPE: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4 ASIA PACIFIC

12.4.1 RECESSION IMPACT: ASIA PACIFIC

FIGURE 65 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT

TABLE 159 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 161 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 162 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 163 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 164 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 166 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 167 ASIA PACIFIC: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4.2 CHINA

12.4.2.1 Growing awareness of benefits of leukapheresis to drive market

FIGURE 66 CHINA: NUMBER OF CAR-T BASED CLINICAL TRIALS REGISTERED (2013–2020)

TABLE 168 CHINA: KEY MACROINDICATORS

TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 170 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 171 CHINA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 172 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 173 CHINA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 174 CHINA: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 175 CHINA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4.3 JAPAN

12.4.3.1 Focus on development of cell therapies to boost market

TABLE 176 JAPAN: KEY MACROINDICATORS

TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 178 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 179 JAPAN: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 180 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 181 JAPAN: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 182 JAPAN: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 183 JAPAN: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4.4 INDIA

12.4.4.1 Rising government investment in healthcare to drive market growth

TABLE 184 INDIA: KEY MACROINDICATORS

TABLE 185 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 186 INDIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 187 INDIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 188 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 189 INDIA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 190 INDIA: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 191 INDIA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4.5 AUSTRALIA

12.4.5.1 Increasing incidence of blood cancer to drive market

TABLE 192 AUSTRALIA: KEY MACROINDICATORS

TABLE 193 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 194 AUSTRALIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 195 AUSTRALIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 196 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 197 AUSTRALIA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 198 AUSTRALIA: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 199 AUSTRALIA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4.6 SOUTH KOREA

12.4.6.1 Increasing research in cell therapy to fuel market growth

TABLE 200 SOUTH KOREA: KEY MACROINDICATORS

TABLE 201 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 202 SOUTH KOREA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 203 SOUTH KOREA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 204 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 205 SOUTH KOREA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 206 SOUTH KOREA: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 207 SOUTH KOREA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.4.7 REST OF ASIA PACIFIC

TABLE 208 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 209 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 210 REST OF ASIA PACIFIC: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 211 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 212 REST OF ASIA PACIFIC: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 213 REST OF ASIA PACIFIC: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 214 REST OF ASIA PACIFIC: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.5 LATIN AMERICA

12.5.1 RECESSION IMPACT: LATIN AMERICA

TABLE 215 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 216 LATIN AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 217 LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 218 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 219 LATIN AMERICA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 220 LATIN AMERICA: LEUKAPHERESIS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 221 LATIN AMERICA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

12.6 MIDDLE EAST & AFRICA

12.6.1 RECESSION IMPACT: MIDDLE EAST & AFRICA

TABLE 222 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 223 MIDDLE EAST & AFRICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 224 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 225 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 226 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 227 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 228 MIDDLE EAST & AFRICA: LEUKAPHERESIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 248)

13.1 INTRODUCTION

13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET

13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS MARKET

13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS

FIGURE 67 LEUKAPHERESIS INDUSTRY: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS

13.4 COMPETITIVE BENCHMARKING (LEUKAPHERESIS MARKET)

TABLE 229 OVERALL COMPANY FOOTPRINT

TABLE 230 COMPANY END USER FOOTPRINT

TABLE 231 COMPANY APPLICATION FOOTPRINT

TABLE 232 COMPANY REGION FOOTPRINT

13.5 MARKET SHARE ANALYSIS (LEUKAPHERESIS PRODUCTS, 2022)

TABLE 233 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION

FIGURE 68 LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER (2022)

13.6 MARKET SHARE ANALYSIS (LEUKOPAKS, 2022)

TABLE 234 LEUKOPAKS MARKET: DEGREE OF COMPETITION

FIGURE 69 LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER (2022)

13.7 COMPANY EVALUATION MATRIX, 2022 (LEUKAPHERESIS MARKET)

13.7.1 STARS

13.7.2 EMERGING LEADERS

13.7.3 PERVASIVE PLAYERS

13.7.4 PARTICIPANTS

FIGURE 70 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION MATRIX (2022)

13.8 COMPETITIVE EVALUATION MATRIX FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2022)

TABLE 235 LEUKAPHERESIS INDUSTRY: KEY START-UPS/SMES

13.8.1 PROGRESSIVE COMPANIES

13.8.2 DYNAMIC COMPANIES

13.8.3 STARTING BLOCKS

13.8.4 RESPONSIVE COMPANIES

FIGURE 71 LEUKAPHERESIS MARKET: SMES/START-UPS COMPANY EVALUATION QUADRANT (2022)

13.9 COMPETITIVE EVALUATION MATRIX, 2022 (LEUKAPHERESIS MARKET)

13.9.1 STARS

13.9.2 EMERGING LEADERS

13.9.3 PERVASIVE PLAYERS

13.9.4 PARTICIPANTS

FIGURE 72 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2022)

13.1 COMPETITIVE SCENARIO AND TRENDS

TABLE 236 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–AUGUST 2023)

TABLE 237 DEALS (JANUARY 2019–AUGUST 2023)

TABLE 238 OTHER DEVELOPMENTS (JANUARY 2019–AUGUST 2023)

14 COMPANY PROFILES (Page No. - 270)

14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)

(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*

14.1.1 TERUMO BCT

TABLE 239 TERUMO BCT: COMPANY OVERVIEW

FIGURE 73 TERUMO BCT: COMPANY SNAPSHOT (2022)

14.1.2 FRESENIUS SE & CO. KGAA

TABLE 240 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW

FIGURE 74 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2022)

14.1.3 HAEMONETICS CORPORATION

TABLE 241 HAEMONETICS CORPORATION: COMPANY OVERVIEW

FIGURE 75 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022)

14.1.4 ASAHI KASEI CORPORATION

TABLE 242 ASAHI KASEI CORPORATION: COMPANY OVERVIEW

FIGURE 76 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)

14.1.5 MACOPHARMA SA

TABLE 243 MACOPHARMA SA: COMPANY OVERVIEW

14.1.6 MILTENYI BIOTEC

TABLE 244 MILTENYI BIOTEC: COMPANY OVERVIEW

14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)

14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.

TABLE 245 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW

14.2.2 MEDICA SPA.

TABLE 246 MEDICA SPA: COMPANY OVERVIEW

14.2.3 PURIBLOOD MEDICAL CO. LTD.

TABLE 247 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW

14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.

TABLE 248 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW

14.2.5 SB-KAWASUMI LABORATORIES, INC.

TABLE 249 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW

14.2.6 NIKKISO CO., LTD.

TABLE 250 NIKKISO CO., LTD.: COMPANY OVERVIEW

FIGURE 77 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)

14.2.7 PALL CORPORATION

TABLE 251 PALL CORPORATION: COMPANY OVERVIEW

14.3 KEY PLAYERS (LEUKAPHERESIS MARKET)

14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

TABLE 252 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW

FIGURE 78 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)

14.3.2 DISCOVERY LIFE SCIENCES, INC.

TABLE 253 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW

14.3.3 BIOIVT

TABLE 254 BIOIVT: COMPANY OVERVIEW

14.3.4 PRECISION FOR MEDICINE, INC.

TABLE 255 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW

14.3.5 STEMEXPRESS, LLC

TABLE 256 STEMEXPRESS, LLC: COMPANY OVERVIEW

14.4 OTHER PLAYERS (LEUKAPHERESIS MARKET)

14.4.1 LONZA GROUP AG

TABLE 257 LONZA GROUP AG: COMPANY OVERVIEW

FIGURE 79 LONZA GROUP AG: COMPANY SNAPSHOT (2022)

14.4.2 CALTAG MEDSYSTEMS LIMITED

TABLE 258 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW

14.4.3 ZENBIO, INC.

TABLE 259 ZENBIO, INC.: COMPANY OVERVIEW

14.4.4 STEMCELL TECHNOLOGIES

14.4.5 TRINA BIOREACTIVES AG

14.4.6 ACCEGEN

14.4.7 FIRST CHOICE BIO LLC

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 321)

15.1 DISCUSSION GUIDE

15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

15.3 CUSTOMIZATION OPTIONS

15.4 RELATED REPORTS

15.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the leukapheresis market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Breakdown of Primary Interviews the Leukapheresis Products Market: Supply-Side Participants by Company Type, Designation, and Region

Leukapheresis Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2022: Tier 1= >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3= <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Breakdown of Primary Interviews in the Leukopaks Market: Supply-Side Participants by Company Type, Designation, and Region

Leukapheresis Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2022: Tier 1= >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3= <USD 500 million

Market Size Estimation

The total size of the leukapheresis market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach. The same approach was used for the leukopaks market.

Leukapheresis Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytosis leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics.

Key Stakeholders

Apheresis Device Manufacturers and Distributors
Leukapheresis Product Manufacturers and Distributors
Leukopak Manufacturers and Distributors
Pharmaceutical and Biotechnology Companies
Healthcare Service Providers (including Hospitals and Transfusion Centers)
Cancer Treatment Centers
Blood Component Providers & Blood Centers
Contract Research Organizations (CROS)
Academic and Research Institutes
Government Associations
Market Research and Consulting Firms
Venture Capitalists and Investors

Objectives of the Study

To define, describe, and forecast the leukapheresis products market by type, application, end-user, and region
To define, describe, and forecast the leukopaks market by type, indication, end-user, and region
To strategically analyze the industry trends, technology trends, pricing analysis, regulatory scenario, supply/value chain, ecosystem/market map, Porter’s Five Forces, trade & patent analysis, key stakeholders & buying criteria, and conferences & events
To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the market size based on region in Europe, North America, the Asia Pacific, Latin America, and the Middle East and Africa
To strategically profile key players in the leukapheresis market and comprehensively analyze their core competencies
To track and analyze competitive developments such as acquisitions, product launches, approvals, expansions, and partnerships
To analyze the impact of the recession on the leukapheresis market

Available customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographic Analysis

Further breakdown of the RoE leukapheresis market into Austria, Finland, and others
Further breakdown of the RoLATAM leukapheresis market into Brazil, Mexico, Argentina, Colombia, Chile, and others

Competitive Landscape Assessment

Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the leukapheresis market
Competitive leadership mapping for established players in the US

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.